Prognostic Biomarkers for COVID-19 Patients: Inhibitory Immune Checkpoint Receptors and Ligands

Hania Szajewska

doi:10.4172/icr.1000119

Immunology: Current Research
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Commentary
Immunol Curr Res 2022, Vol 6(3): 119
DOI: 10.4172/icr.1000119

Prognostic Biomarkers for COVID-19 Patients: Inhibitory Immune Checkpoint Receptors and Ligands

Hania Szajewska^*: Department of Paediatrics, The Medical University of Warsaw, Warsaw, Poland

^*Corresponding Author : Hania Szajewska, Department of Paediatrics, The Medical University of Warsaw, Warsaw, Poland, Email: hanias@gmail.com

Received Date: Apr 13, 2022 / Published Date: May 11, 2022

View PDF Download PDF

Citation: Szajewska H (2022) Prognostic Biomarkers for COVID-19 Patients: Inhibitory Immune Checkpoint Receptors and Ligands. Immunol Curr Res, 6: 119. Doi: 10.4172/icr.1000119

Copyright: © 2022 Szajewska H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.